Skip to content

NMIN’s Founding Scientific Director wins VinFuture Foundation’s first global sci-tech award

Canadian nanomedicine scientist and NMIN founder Dr. Pieter Cullis, together with his Germany and US-based peers Drs Katalin Kariko and Drew Weissman, have been honoured with the inaugural VinFuture Grand Prize for their contributions to the development of COVID-19 messenger RNA (mRNA) vaccines. Dr. Cullis and colleagues at the University… Read More »NMIN’s Founding Scientific Director wins VinFuture Foundation’s first global sci-tech award

Company led by NMIN’s Dr. John Lewis named BioAlberta’s Company of the Year 2020

Entos Pharmaceuticals Inc., led by NMIN researcher Dr. John Lewis, has received the 2020 BioAlberta Achievement award for Company of the Year. At its 16 November 2021 AGM, BioAlberta announced the recipients of its 2020 Achievement Awards, recognizing individuals and companies who have contributed to the success of Alberta’s life… Read More »Company led by NMIN’s Dr. John Lewis named BioAlberta’s Company of the Year 2020

Canadian scientist awarded international prize for COVID vaccine technology

Canadian scientist Dr. Pieter Cullis, together with his peers Drs Katalin Kariko and Drew Weissman, have been honoured with the 2021 Prince Mahidol Award for their contributions to the development of COVID-19 messenger RNA (mRNA) vaccines. Through over 40 years of work in his University of British Columbia (UBC) laboratory,… Read More »Canadian scientist awarded international prize for COVID vaccine technology

2021 NMIN Postdoctoral Fellowship in Gene Therapy winner announced

The NanoMedicines Innovation Network (NMIN) is pleased to announce the recipient of its 2021 NMIN Postdoctoral Fellowship in Gene Therapy: Dr. Miffy Hok Yan Cheng. The awardee was selected by the members of NMIN’s Research Management Committee, based on the applicant’s qualifications, as well as the quality of the proposed… Read More »2021 NMIN Postdoctoral Fellowship in Gene Therapy winner announced

Meet Rasika Kulkarni, NMIN’s new Manager, Research Administration

As of 19 October 2021, NMIN has a new Manager, Research Administration: Dr. Rasika Kulkarni, MSc, PhD. Dr. Kulkarni holds a Doctorate in Microbiology, with multidisciplinary expertise in molecular biology, nanotechnology and medical microbiology. She has experience in protocol development and validation, laboratory and diagnostic testing and analysis, scientific writing,… Read More »Meet Rasika Kulkarni, NMIN’s new Manager, Research Administration

Acuitas Therapeutics wins Global Impact Award for LNPs in COVID vaccines

https://youtu.be/AuEkO4Ge-q4 Thomas Madden (Acuitas) interviewed on Global TV Acuitas Therapeutics, the Vancouver, BC-based biotech company co-founded by NMIN research leader Dr. Pieter Cullis, has been granted a Global Impact Award by Life Sciences British Columbia, in recognition of the company’s “extraordinary leadership and efforts they made in the development of… Read More »Acuitas Therapeutics wins Global Impact Award for LNPs in COVID vaccines

LNPs & mRNA vaccines: Dr. Pieter Cullis in Nature Reviews Materials

“There is no time like the present to try to achieve impossible dreams” The contributions of NMIN Research Leader Dr. Pieter Cullis toward enabling effective mRNA vaccines, most notably against COVID-19, continue to garner high-profile recognition. Most recently, Dr. Cullis was featured on CBC’s Quirks & Quarks; his role was… Read More »LNPs & mRNA vaccines: Dr. Pieter Cullis in Nature Reviews Materials

First recipients of NMIN’s Advanced Training Certification (ATC) announced

The NanoMedicines Innovation Network (NMIN) is pleased to announce the inaugural recipients of NMIN Advanced Training Certification (ATC). NMIN ATC recognizes an individual’s engagement in diverse capacity-building activities organized by NMIN, its partners, and/or other recognized organizations, where the learning involved goes “above and beyond” the training conventionally provided in… Read More »First recipients of NMIN’s Advanced Training Certification (ATC) announced